Journal of Clinical Oncology
Articles in this Issue
Patient perspectives on active surveillance and machine learning–driven risk stratification for low-risk breast cancer.
e13776 Background: Growing evidence suggests that overdiagnosis from routine screening may result in overtreatment among o...
Survival outcomes of upfront surgery versus systemic therapy followed by surgery in patients with synchronous pancreatic ductal adenocarcinoma and liver metastases: A multicenter retrospective cohort study.
e16370 Background: The optimal treatment strategy for patients with synchronous pancreatic ductal adenocarcinoma with live...
Utilization patterns of venetoclax-based regimens for AML in a community-based setting and representative populational analyses.
e18621 Background: Azacitidine with Venetoclax was approved in 2020 for older patients ineligible for intensive chemothera...
From concept to clinic: Implementation and early outcomes of MCED screening at RUSH Health System.
e13591 Background: Approximately one-third of Americans will develop cancer, yet guideline-recommended screening exists fo...
Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein–targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC).
5514 Background: c-Met protein is expressed in several tumor types, including PROC, and is linked with poor clinical outco...
Immunotherapy use without approval: Patterns, biases, and biomarkers in patients with ovarian cancer.
e17588 Background: Immunotherapy use has attracted increasing attention in ovarian cancer but currently has no disease spe...
Challenges and strategies for multidisciplinary care of ocular adverse events: Real-world perspectives from oncologists and eye specialists.
e23436 Background: Advances in antibody-drug conjugates (ADCs) offer potential for enhanced efficacy with reduced systemic...
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas.
e13526 Background: Recent therapeutic advances have significantly improved outcomes in many chronic hematological malignan...
Impact of adalimumab on mortality and cancer risk in patients with inflammatory diseases.
e24131 Background: Adalimumab is a commonly used medication for diverse inflammatory conditions. More information is requi...
UTOPIA: A phase 3 trial of UGN-103, an intravesical mitomycin reverse thermal hydrogel, in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
4604 Background: Management of recurrent low-grade (LG), intermediate-risk (IR) non-muscle invasive bladder cancer (NMIBC)...
Long-term hair loss associated with brentuximab vedotin–containing chemotherapy and its psychosocial impact: A retrospective observational study conducted at the Royal Marsden Hospital.
e19036 Background: Alopecia is a recognised toxicity of Brentuximab Vedotin (BV), but data on the duration and long-term p...
Parent willingness to enroll children with acute lymphoblastic leukemia in escalation and de-escalation clinical trials.
12098 Background: Patient and parent willingness to participate in clinical trials has and will continue to be essential t...
Subgroup analysis of participants (pts) with HER2 IHC0 in the ASCENT-07 study of sacituzumab govitecan (SG) vs chemotherapy in HR+/ HER2− metastatic breast cancer (mBC).
1065 Background: SG was evaluated in the phase 3 ASCENT-07 study (NCT05840211) of pts with HR+/HER2−, locally advanced unr...
Initial phase 1 study results of NT-175 engineered T-cell therapy in <i>TP53</i> R175H–mutated unresectable advanced solid tumors.
2506 Background: TP53 is the most frequently mutated tumor suppressor gene across various tumor types,...
AI-driven large language models for multimodal prediction of homologous recombination deficiency using clinical features and histopathological whole-slide images.
548 Background: Homologous recombination deficiency (HRD) implies the dysfunction of homologous recombination repair at th...
Characteristics of <i>SMAD4</i> alterations in an immune-cold genomic subtype of biliary tract cancers in the Indian population.
4151 Background: Biliary tract cancers (BTCs), comprising gallbladder cancer (GBC) and cholangiocarcinoma (CCA), are rare...
Intratumoral spatial distribution of high-risk prostate cancer patterns: Evaluation on digital pathology.
e17123 Background: The most recent guidelines from the European Urology Association (EUA) have recommended implementation...
Development and external validation of a computational approach for accelerated read out of randomized clinical trials in metastatic prostate cancer.
1502 Background: While overall survival (OS) is the gold standard endpoint for clinical trials in metastatic prostate canc...
Genetic susceptibility between psychiatric disorders and gynecologic cancers: A systematic review.
e22506 Background: Depression rates in women with cancer are notably increased, impacting quality of life and disease prog...
Effect of biennial mammography on stage at diagnosis and outcomes of breast cancer in the Brazilian public health system.
e23371 Background: Breast cancer is the leading cause of cancer-related death among women in Brazil. Biennial mammography...
Real-world and randomized clinical trial comparison in patients with m <i>IDH1</i> CCA treated with ivosidenib: ProvIDHe vs ClarIDHy.
e16173 Background: Cholangiocarcinoma (CCA) is a rare disease, and most patients are diagnosed at an advanced stage. Ivosi...
AMPLIFY: A phase 3 study of <sup>64</sup> Cu-SAR-bisPSMA positron emission tomography in participants with biochemical recurrence of prostate cancer.
TPS5151 Background: Prostate cancer (PC) is the second most prevalent cancer in men globally. The need for improved PC ima...
Impact of neutrophil-to-lymphocyte ratio on pathological response in HER2-positive breast cancer patients: A retrospective analysis.
e12577 Background: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) combined with HER2-targeted t...
Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544, plus next-generation BRAF dimer inhibitor, PF-07799933, in advanced <i>BRAF</i> -mutant melanoma.
9512 Background: Treatment of BRAF -mutant (mut) melanoma has been transformed by...
Transdermal drug delivery to the normal and the radiated breast: Determinants of individual variation in skin permeation.
10570 Background: Primary prevention of breast cancer with oral drugs causes systemic effects which are unacceptable to 85...